RT-qPCR revealed that the novel menin-MLL inhibitor Revumenib did not inhibit the transcription of those lysosomal and autophagic genes in the leukemia cell lines of MV4-11 and THP-1 (Supplementary Fig. S5H). This evidence concerns the gene KMT2A and leukemia.